Innovation in ophtha made in Italy: NTC has developed the first combination of levofloxacin and dexamethasone eye drops

  • May 13, 2021

NTC, an Italian pharmaceutical company specializing in ophthalmology, has developed the first eyedrops containing a fluoroquinolone wide spectrum antibiotic and a standard of care cortisone for the post-surgical treatment of cataract. The drug reduces the duration of therapy after surgery by 50%.

NTC grants to Zhaoke exclusive license and distribution rights in Asia for NTC014, innovative drug for bacterial conjunctivitis

  • Jan 14, 2021

NTC, an international R&D focused pharmaceutical company headquartered in Italy, and Zhaoke (Hong Kong) Ophthalmology Pharmaceuticals Limited, having a fully integrated ophthalmic platform with strong foundation in eyecare, announce today their agreement for exclusive license and distribution rights of NTC014, innovative fixed combination of a quinolone antibiotic and a NSAID in eye drops.

New CE certifications for three NTC products based on tiab technology

  • Jul 22, 2020

NTC Srl, R&D focused pharmaceutical company headquartered in Italy, has obtained CE certifications for three medical devices based on TIAB technology: a new vaginal gel GENIGEL, a proctological cream-gel TIAHEM and a powder for wound care TIAHEL.

NTC grants license and distribution rights in Israel to Taro Pharmaceutical Industries

  • Jun 17, 2020

NTC Srl, an R&D focused pharmaceutical company headquartered in Italy, has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries (”Taro”), a research-based international pharmaceutical company.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. READ MORE